Published in Lab Business Week, January 14th, 2007
These changes highlight leading developments in the treatment of breast cancer and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings.
Based on results from the study of Tamoxifen and Raloxifene (STAR) trial, a panel of added Raloxifene (Evista, Eli Lilly and Company) as an option for reducing the risk of invasive breast cancer in postmenopausal women with lobular carcinoma in situ.
The accuracy of HER2 assays...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.